AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33155357 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative isometric exercises (EG)
Number of subjects: 27
Study 33155357 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 27
Study 34218941 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 0
Study 34218941 — intervention group
Group type: COMPARATOR
Intervention: 2-Dimensional Full Field Digital Mammography (FFDM)
Number of subjects: 0
Study 33218560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Number of subjects: 35
Study 33218560 — intervention group
Group type: COMPARATOR
Intervention: Placebo diacutaneous fibrolysis
Number of subjects: 35
Study 36239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 2.5 IU
Number of subjects: 40
Study 36239406 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin 100 μg
Number of subjects: 40
Study 36239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Oxytocin and Carbetocin
Number of subjects: 40
Study 34288591 — intervention group
Group type: EXPERIMENTAL
Intervention: Home infusions of natalizumab (n=18)
Number of subjects: 37
Study 34288591 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital out‐patients’ clinic) (n=19)
Number of subjects: 37
Study 32781869 — intervention group
Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment (2 treatments for 30 min per day for 6 days)
Number of subjects: 71
Study 32781869 — intervention group
Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment
Number of subjects: 71
Study 32781869 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID therapy reduction
Number of subjects: 71
Study 35949389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Relief Kit
Number of subjects: 53
Study 35949389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 32591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI-4736)
Number of subjects: 46
Study 32591370 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy
Number of subjects: 46
Study 34579142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle, Exercise, and Nutrition (LEAN) Study
Number of subjects: 100
Study 34579142 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 35064733 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal behavioural intervention (intensive contact schedule, education, motivational interviewing, value-based activity planning during 12 weeks)
Number of subjects: 179
Study 35064733 — intervention group
Group type: COMPARATOR
Intervention: Minimal behavioural intervention (short contact only)
Number of subjects: 179
Study 35064733 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal behavioural intervention
Number of subjects: 179
Study 35064733 — intervention group
Group type: COMPARATOR
Intervention: Minimal behavioural intervention
Number of subjects: 179
Study 33021110 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide as an adjunctive treatment to levodopa
Number of subjects: 0
Study 33021110 — intervention group
Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 0
Study 37115133 — intervention group
Group type: COMPARATOR
Intervention: Polypharmacy (≥5 medications excluding HFrEF GDMT) at baseline
Number of subjects: 891
Study 37115133 — intervention group
Group type: EXPERIMENTAL
Intervention: No polypharmacy (<5 medications) at baseline
Number of subjects: 891
Study 37115133 — intervention group
Group type: COMPARATOR
Intervention: Polypharmacy at baseline
Number of subjects: 891
Study 37115133 — intervention group
Group type: EXPERIMENTAL
Intervention: No polypharmacy at baseline
Number of subjects: 891
Study 32914554 — intervention group
Group type: COMPARATOR
Intervention: Cornea Max (serum‐based)
Number of subjects: 64
Study 32914554 — intervention group
Group type: COMPARATOR
Intervention: Cornea Syn (synthetic)
Number of subjects: 64
Study 32914554 — intervention group
Group type: EXPERIMENTAL
Intervention: Human corneal endothelial cell (HCEnC) culture
Number of subjects: 64
Study 32754930 — intervention group
Group type: EXPERIMENTAL
Intervention: Essentialist thinking toward biosocial risk factors for criminality
Number of subjects: 897
Study 32754930 — intervention group
Group type: EXPERIMENTAL
Intervention: Essentialist thinking toward types of offending
Number of subjects: 897
Study 32754930 — intervention group
Group type: EXPERIMENTAL
Intervention: Essentialist thinking toward discreteness and informativeness
Number of subjects: 897
Study 33448466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone-ester (395 mg/kg) + carbohydrate drink (30 g)
Number of subjects: 6
Study 33448466 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate drink (66 g)
Number of subjects: 6
Study 33080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with deqi
Number of subjects: 108
Study 33080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture without deqi
Number of subjects: 108
Study 33080693 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 108
Study 34251539 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leg heating intervention (EXP) - immersion in 42.5℃ water for five 35-min sessions/week for 8 weeks
Number of subjects: 13
Study 34251539 — intervention group
Group type: COMPARATOR
Intervention: Control leg (CON)
Number of subjects: 13
Study 34791237 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn ActiGraph accelerometer
Number of subjects: 0
Study 34791237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-worn ActiGraph accelerometer
Number of subjects: 0
Study 32304003 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary atherectomy (ELCA) prior to paclitaxel-coated balloon angioplasty
Number of subjects: 118
Study 32304003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ELCA)
Number of subjects: 118
Study 33238818 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven coaching that integrated observational assessment and performance feedback
Number of subjects: 106
Study 33238818 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven coaching for SE teachers
Number of subjects: 106
Study 33238818 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no coaching)
Number of subjects: 106
Study 36088609 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminor® 35 drug‐coated balloon (DCB) angioplasty
Number of subjects: 171
Study 36088609 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 171
Study 34779646 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib with or without bevacizumab
Number of subjects: 0
Study 34779646 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil plus bevacizumab
Number of subjects: 0
Study 35662491 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Early Learning intervention
Number of subjects: 314
Study 35662491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study 33430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group (S)
Number of subjects: 239
Study 33430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance group (E)
Number of subjects: 239
Study 33430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance group (SE)
Number of subjects: 239
Study 33430216 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 239
Study 32174446 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible pacing during assembly of customised products
Number of subjects: 0
Study 32174446 — intervention group
Group type: COMPARATOR
Intervention: Restrictive pacing during assembly of customised products
Number of subjects: 0
Study 35270595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 15
Study 35270595 — intervention group
Group type: COMPARATOR
Intervention: Nicotine vaping
Number of subjects: 15
Study 35270595 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free vaping
Number of subjects: 15
Study 32584155 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-T03 (videogame-like digital treatment)
Number of subjects: 0
Study 32584155 — intervention group
Group type: COMPARATOR
Intervention: AKL-T09 (control word game)
Number of subjects: 0
Study 33600134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg, three monthly doses
Number of subjects: 50
Study 32826003 — intervention group
Group type: EXPERIMENTAL
Intervention: Active WBV (35 Hz)
Number of subjects: 28
Study 32826003 — intervention group
Group type: COMPARATOR
Intervention: Sham WBV
Number of subjects: 28
Study 35177515 — intervention group
Group type: EXPERIMENTAL
Intervention: Previsit patient activation card
Number of subjects: 120
Study 35177515 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 34214704 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic esophagitis (EoE)
Number of subjects: 786
Study 34214704 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-eosinophilic gastrointestinal disorders (non-EoE EGIDs)
Number of subjects: 786
Study 34214704 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-EoE EGIDs in children
Number of subjects: 786
Study 36368325 — intervention group
Group type: EXPERIMENTAL
Intervention: relatively easy criteria for success (RES)
Number of subjects: 48
Study 36368325 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 48
Study 33751849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 765
Study 32527353 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing
Number of subjects: 80
Study 32527353 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 33476425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS with 2000 pulses
Number of subjects: 22
Study 33476425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz with 500 pulses per session
Number of subjects: 22
Study 33476425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz with 500 pulses per session
Number of subjects: 22
Study 33476425 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 22
Study 34223734 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Genistein (GEN)
Number of subjects: 80
Study 32120880 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity break (10 min of moderate intensity activities such as star jumps)
Number of subjects: 68
Study 32120880 — intervention group
Group type: COMPARATOR
Intervention: Control condition (10 min of playing a vocabulary game)
Number of subjects: 68
Study 35467040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia veneered with feldspar ceramics
Number of subjects: 20
Study 35467040 — intervention group
Group type: COMPARATOR
Intervention: Titanium
Number of subjects: 20
Study 35467040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 20
Study 35467040 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK
Number of subjects: 20
Study 33368319 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day stored RBCs
Number of subjects: 30
Study 33368319 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-day stored RBCs
Number of subjects: 30
Study 33368319 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day stored RBCs
Number of subjects: 30
Study 32664066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse or pharmacist-led aggressive control of comorbidities
Number of subjects: 400
Study 32664066 — intervention group
Group type: COMPARATOR
Intervention: Currently practiced best risk factor management strategies
Number of subjects: 400
Study 35426763 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced basketball players
Number of subjects: 48
Study 35426763 — intervention group
Group type: COMPARATOR
Intervention: Novice basketball players
Number of subjects: 48
Study 35426763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 32749733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1000
Study 32749733 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only (Control)
Number of subjects: 1000
Study 36308446 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulated group (warfarin + aspirin)
Number of subjects: 140
Study 36308446 — intervention group
Group type: COMPARATOR
Intervention: Control group (aspirin only)
Number of subjects: 140
Study 34597899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepranolone 10 mg
Number of subjects: 206
Study 34597899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepranolone 16 mg
Number of subjects: 206
Study 34597899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 32464527 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP intervention (community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral)
Number of subjects: 15013
Study 32464527 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP intervention with ≥8 contacts
Number of subjects: 15013
Study 32464527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CLIP contacts)
Number of subjects: 15013
Study 35468266 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based outpatient physical therapy delivered 6 weeks after TKR, costing £179 ± 39 per patient.
Number of subjects: 180
Study 35468266 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 180
Study 35189843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based video intervention about IPV and safety behaviours
Number of subjects: 317
Study 35189843 — intervention group
Group type: COMPARATOR
Intervention: Control video promoting healthy pregnancy
Number of subjects: 317
Study 34049809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% HA eye drops during hydrogel SCL wear
Number of subjects: 20
Study 34049809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% HA eye drops during hydrogel SCL wear
Number of subjects: 20
Study 34049809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% HA eye drops during silicone-hydrogel SCL wear
Number of subjects: 20
Study 34049809 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 33040096 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of mobile phone use over time
Number of subjects: 64
Study 33040096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and sensory distractions
Number of subjects: 64
Study 35456220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin A (BT‐A) injection
Number of subjects: 46
Study 35456220 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 46
Study 35456220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin A (BT‐A) injection (BMI > 50 kg/m2)
Number of subjects: 46
Study 35456220 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control) (BMI > 50 kg/m2)
Number of subjects: 46
Study 32286882 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of supervised, moderate-intensity aerobic exercise
Number of subjects: 27
Study 32286882 — intervention group
Group type: COMPARATOR
Intervention: Conventional lifestyle advice
Number of subjects: 27
Study 34583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 4238
Study 34583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification system
Number of subjects: 4238
Study 34583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 4238
Study 34583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Curve Analyses (DCAs)
Number of subjects: 4238
Study 34583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 4238
Study 36246130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise group (AerG)
Number of subjects: 102
Study 36246130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval aerobic exercise group (IntG)
Number of subjects: 102
Study 36246130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise group (ComG)
Number of subjects: 102
Study 36246130 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 102
Study 33354715 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 109
Study 33354715 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 109
Study 35667527 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) planned for 332 lesions in 296 separate PTVs, with common prescriptions of 30-35 Gy in 5 fractions (43% of lesions) and 20-24 Gy in 1 fraction (33% of lesions).
Number of subjects: 60
Study 35667527 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) for spinal targets.
Number of subjects: 60
Study 35667527 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) for lymph node targets.
Number of subjects: 60
Study 32655007 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin
Number of subjects: 325
Study 32655007 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin
Number of subjects: 325
Study 32655007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 36351419 — intervention group
Group type: EXPERIMENTAL
Intervention: Static posturography‐assisted biofeedback exercises (n=20)
Number of subjects: 41
Study 36351419 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program (n=21)
Number of subjects: 41
Study 33528816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-period design with varying weekly measurement schemes
Number of subjects: 0
Study 33528816 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned missing data designs
Number of subjects: 0
Study 33528816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout modeled by the Weibull survival function
Number of subjects: 0
Study 33528816 — intervention group
Group type: EXPERIMENTAL
Intervention: Few subjects per day and a large number of weeks
Number of subjects: 0
Study 33528816 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting room environments in dental care
Number of subjects: 0
Study 36379663 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms clinic intervention plus usual care
Number of subjects: 354
Study 36379663 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 354
Study 33629536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha
Number of subjects: 98
Study 33629536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 32343882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 1148
Study 32343882 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 1148
Study 32343882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg plus MTX
Number of subjects: 1148
Study 32343882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg plus MTX
Number of subjects: 1148
Study 32343882 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 1148
Study 34143354 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for primary care providers
Number of subjects: 36
Study 34143354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 36
Study 34836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 256
Study 34836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher prostaglandin E2 (PGE2) levels
Number of subjects: 256
Study 34836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 5-hydroxyeicosatetraenoic acid (5-HETE) levels
Number of subjects: 256
Study 34836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PGE2 levels
Number of subjects: 256
Study 34836131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylipins
Number of subjects: 256
Study 34905388 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC-FO
Number of subjects: 262
Study 34905388 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 262
Study 34905388 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC-FO responders
Number of subjects: 262
Study 36205271 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 77
Study 36205271 — intervention group
Group type: COMPARATOR
Intervention: Traditional Faculty-led Teaching (non-PAL)
Number of subjects: 77
Study 36205271 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAL and non-PAL
Number of subjects: 77
Study 33908117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum (0.2 mL of human milk)
Number of subjects: 260
Study 33908117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2 mL of placebo)
Number of subjects: 260
Study 33908117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Number of subjects: 260
Study 33908117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 32045077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical psychologist‐facilitated group intervention (9 groups over 3 weeks)
Number of subjects: 238
Study 32045077 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 238
Study 35908296 — intervention group
Group type: EXPERIMENTAL
Intervention: immediate-use App (iApp group; n = 47)
Number of subjects: 95
Study 35908296 — intervention group
Group type: COMPARATOR
Intervention: delayed-use App (dApp group; n = 48)
Number of subjects: 95
Study 33691699 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise CMD risk assessment and individualized treatment
Number of subjects: 1934
Study 33691699 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1934
Study 32125052 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Conversational Agent (VCA) interface
Number of subjects: 50